
Nygen Analytics AB is a Swedish company revolutionizing single-cell multi-omics data analysis with a scalable cloud platform designed for bench scientists and researchers in biopharma, biotech, and academia. Their product suite includes Nygen Analytics for intuitive, no-code single-cell data analysis, Nygen Database for accessing curated single-cell datasets, and Nygen Insights leveraging AI for actionable research insights. The platform features advanced AI-enabled cell characterization, collaborative bioinformatics analysis, and industry-leading security certifications (ISO 27001, SOC 2). Nygen supports drug discovery through cell atlases, accelerating target validation and personalized medicine. Headquartered in Lund, Sweden, Nygen serves over 1500 researchers worldwide, offering transparent pricing and dedicated bioinformatics services to accelerate discovery and therapeutic development.

Nygen Analytics AB is a Swedish company revolutionizing single-cell multi-omics data analysis with a scalable cloud platform designed for bench scientists and researchers in biopharma, biotech, and academia. Their product suite includes Nygen Analytics for intuitive, no-code single-cell data analysis, Nygen Database for accessing curated single-cell datasets, and Nygen Insights leveraging AI for actionable research insights. The platform features advanced AI-enabled cell characterization, collaborative bioinformatics analysis, and industry-leading security certifications (ISO 27001, SOC 2). Nygen supports drug discovery through cell atlases, accelerating target validation and personalized medicine. Headquartered in Lund, Sweden, Nygen serves over 1500 researchers worldwide, offering transparent pricing and dedicated bioinformatics services to accelerate discovery and therapeutic development.
Headquarters: Lund, Sweden (Medicon Village)
Founded: 2022
Product: Cloud-first, AI-augmented single-cell & multi-omics analytics platform
Customers: Serves researchers in academia, biotech and pharma
Security & Compliance: Claims ISO 27001 and SOC 2; GDPR adherence stated
Seed (Aug 29, 2024)
Single-cell transcriptomics and multi-omics data analysis for research and drug discovery
2022
Biotechnology
Most recent round reported on Aug 29, 2024; company lists investors including Fåhraeus Startup and Growth and SmiLe Inject Capital.
“SmiLe Inject Capital; Fåhraeus Startup and Growth”